Important Notice

You are now leaving the Averitas Pharma, Inc. website and will be redirected to a site intended for an international audience. Please be aware that the content, products, and services on the international site may differ from those on our U.S. site and may not be approved for a U.S. audience.

Click "Continue" if you wish to proceed to the international site, or "Cancel" to stay on the current page.

Changing Lives for the Better

We approach pain as a disease in urgent need of a solution, rather than a mere symptom. Our empathy for patients, and our shared sense of mission and purpose, are what inspire us.


people live with unresolved diabetic nerve pain despite trying other first-line treatments.

Diabetic peripheral neuropathy (DPN) of the feet occurs if nerves are damaged as a result of diabetes. Damaged nerves cannot correctly transmit signals from the periphery to the central nervous system, causing the signals to be exaggerated and resulting in debilitating pain.


of shingles patients aged ≥50 years develop PHN.

Postherpetic neuralgia (PHN), also known as post-shingles nerve pain, occurs if nerves are damaged due to a previous herpes zoster infection, commonly known as shingles. Damaged nerves cannot correctly transmit signals from from the periphery to the central nervous system, which can cause chronic and debilitating pain.

Building on the more than 75-year legacy of our parent company, Grünenthal

We are proud of our heritage and honor it by working tirelessly toward a world free of pain.

Who We Are

Our people are the key to our success. We are known as entrepreneurs, pioneering thinkers and innovators.

Leadership team members Marv Kelly and Jeannie Lloyds are shown listening to a presentation at a company-wide conference

Are You Ready to Join Forces?

Come see how drawing on our collective strengths helps us deliver on our ambitious goals.